Business
West Reports Fourth-Quarter and Full-Year 2025 Results
West Pharmaceutical Services, Inc. (NYSE: WST), a leading provider of innovative, high-quality injectable solutions and services, today reported its financial results for the fourth quarter and full year 2025.
About this update from West Pharmaceutical Services, Inc.
[{"type":"text","content":"– Strong 4Q results, driven by double-digit organic revenue growth in HVP Components –","length":86,"tagName":"p","attribs":{}},{"type":"text","content":"– Introduces Fiscal 2026 Financial Guidance –","length":45,"tagName":"p","attribs":{}},{"type":"text","content":"EXTON, Pa., Feb. 12, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a leading provider of innovative, high-quality injectable solutions and services, today reported its financial results for the fourth quarter and full year 2025.","length":251,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/West Pharmaceutical Services, I)","displaySize":"","headline":null,"caption":"(PRNewsfoto/West Pharmaceutical Services, I)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":229,"url":"https://media.zenfs.com/en/prnewswire.com/383a8fcc44e20b256017f1f96ff3cc3f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/3TDEWRbeu.AWaitE8z7Y9g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQwNDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/383a8fcc44e20b256017f1f96ff3cc3f","width":400,"height":229}},"href":"https://mma.prnewswire.com/media/890850/west_pharma_large_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Fourth-Quarter and Full-Year 2025 Summary (comparisons to prior-year period)","length":76,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Fourth-quarter net sales of $805.0 million increased 7.5%; organic growth was 3.3%.","length":83,"tagName":"p"}]},{"val":[{"type":"text","content":"Fourth-quarter diluted earnings per share (EPS) of $1.82 increased 2.2%.","length":72,"tagName":"p"}]},{"val":[{"type":"text","content":"Fourth-quarter Adjusted-diluted EPS of $2.04 increased 12.1%.","length":61,"tagName":"p"}]},{"val":[{"type":"text","content":"Full-year net sales of $3.074 billion increased 6.3%; organic growth was 4.3%.","length":78,"tagName":"p"}]},{"val":[{"type":"text","content":"Full-year Diluted EPS of $6.79 increased 1.5%.","length":46,"tagName":"p"}]},{"val":[{"type":"text","content":"Full-year Adjusted-diluted EPS of $7.29 increased 8.0%.","length":55,"tagName":"p"}]},{"val":[{"type":"text","content":"Operating cash flow was $754.8 million, an increase of 15.5%. Capital expenditures were $285.9 million. Free cash flow (defined as operating cash flow less capital expenditu...